Vendor Intelligence Report: Bfflink

Executive summary

Across 40 Finnrick lab tests, Bfflink records 29 pass / 10 fail — a 73% overall pass rate. The record is sharply product-specific: Retatrutide is the more defensible Bfflink choice, while Tirzepatide is the weak point and carries the most serious label-trust risk. The full report also shows why ratings become less forgiving under stricter methodology, especially where fill accuracy matters.

This is not a blanket safe/unsafe verdict. Retatrutide tests materially stronger, but still has enough failures to require current batch verification. Tirzepatide is where the risk changes category: Finnrick evidence includes a major overfill against a labeled vial and a separate no-active-ingredient event, making blind dosing from the label a poor tradeoff.

The non-lab record is equally important. Wayback and WHOIS materials show an older-looking domain history that does not equal a long-running peptide company, a claimed UK-style LTD name that does not verify in the primary registry check, and a predecessor-domain trail with exposed registrant leads. Bfflink also appears to have moved from public storefront access toward email, Signal, and private product links, while a newer privacy-protected domain combines AMO/BFF branding without yet authenticating itself as an official successor.

Positive buyer chatter and fast-delivery reports exist, but they do not solve the core recourse problem: hidden ownership, weak COA availability, irreversible payment rails, and private-link authentication risk. For buyers insisting on Bfflink, the report supports stricter product selection, channel verification, and batch-specific testing before relying on any vial label.

Inside the full report:

• Per-product Finnrick interpretation, methodology-divergence charts, and Appendix A laboratory data for both tested products
• Wayback chronology separating the aged bfflink.com domain from the current AMO/BFF peptide operation
• UK Companies House check and corporate-identity analysis for the claimed BFFLINK Biotechnology LTD name
• WHOIS comparison across bfflist.org, bfflink.com, and the newer bffpeptides.com domain lead
• Private-link ordering, payment, shipping, COA, and dispute-resolution risk assessment
• Buyer verification guidance for distinguishing historical Bfflink channels from unauthenticated links or successor domains

Risk assessment

• Tirzepatide dosing and identity-failure risk — high: Tirzepatide is 71.03% across 18 tests (12 pass / 6 fail); field-captured Finnrick evidence documents a 60 mg-labeled vial testing at 102 mg and a separate no-active-ingredient event.
• Retatrutide dosing-variability risk — medium: Retatrutide is stronger at 81.05% across 21 tests (17 pass / 4 fail), but four failed tests make batch-specific verification necessary.
• Corporate-identity and ownership-opacity concern — high: BFFLINK Biotechnology LTD was not found at UK Companies House; the operator is identified only as Binh with privacy-protected domains and encrypted contacts.
• Private-link brand-authentication and operational-continuity risk — high: bfflink.com has been inaccessible to general visitors, ordering reportedly moved to Signal/email/private links, and bffpeptides.com creates unresolved brand-authentication risk without an official-channel list.
• COA accountability and dispute-resolution concern — high: Archived lab-results page showed no vendor test data, and forum records report refusal to provide a COA or replacement after a product-failure complaint.
• Shipping/payment recourse risk — medium: US-warehouse fulfillment appears optional or stock-dependent, tracking was reportedly withheld for security reasons, and Zelle/Wise/USDT reduce practical recourse.
• Formulation adverse-reaction risk — medium: AMO/BFF forum reports describe prolonged burning or stinging injection-site reactions, with no published excipient or formulation documentation.